Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Statewide Implementation of Sexual Orientation and Gender Identity (SOGI) Data Collection to Advance Health Equity

NCT07904078 is registered in ClinicalTrials.gov with Pacific Institute for Research and Evaluation as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07904078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Statewide Implementation of Sexual Orientation and Gender Identity (SOGI) Data Collection to Advance Health Equity
Lead sponsor
Pacific Institute for Research and Evaluation
Phase
Not applicable
Overall status
Recruiting
Start date
November 30, 2026
Completion date
June 30, 2030
Enrollment
1,320 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

implementation strategies

Arms

As registered; 6 arms.

  • Training Alone - 1 ExperimentalTraining

    Public Health Offices (PHOs) in this arm receive training in phase 1 (months 1-4).

    PHOs are then randomized to continue training in phase 2 (months 5-10). Due to responding to training only, PHOs continue with training only through phase 3 (months 11-16). In phase 4 (months 17-22), implementation support is discontinued.

  • Training Alone - 2 ExperimentalTraining

    Public Health Offices (PHOs) in this arm receive training in phase 1 (months 1-4).

    PHOs are then randomized to continue training in phase 2 (months 5-10). Due to not responding to training only, PHOs are randomized to continue with training only through phase 3 (months 11-16). In phase 4 (months 17-22), implementation support is discontinued.

  • Training + Implementation Strategy 2 ExperimentalImplementation Strategy 2, Training

    Public Health Offices (PHOs) in this arm receive training in phase 1 (months 1-4).

    PHOs are then randomized to continue training in phase 2 (months 5-10). Due to not responding to training only, PHOs are randomized to continue with training and to receive an additional implementation strategy (implementation strategy 2) through phase 3 (months 11-16). In phase 4 (months 17-22), implementation support is discontinued.

  • Training and Implementation Strategy 1-1 ExperimentalImplementation Strategy 1, Training

    Public Health Offices (PHOs) in this arm receive training in phase 1 (months 1-4).

    PHOs are then randomized to continue training and receive an additional implementation strategy (implementation strategy 1) in phase 2 (months 5-10). Due to responding to training and implementation strategy 1, PHOs continue with training and implementation strategy 1 through phase 3 (months 11-16). In phase 4 (months 17-22), implementation support is discontinued.

  • Training and Implementation Strategy 1-2 ExperimentalImplementation Strategy 1, Training

    Public Health Offices (PHOs) in this arm receive training in phase 1 (months 1-4).

    PHOs are then randomized to continue training and receive an additional implementation strategy (implementation strategy 1) in phase 2 (months 5-10). Due to not responding to training and implementation strategy 1, PHOs continue with training and implementation strategy 1 through phase 3 (months 11-16). In phase 4 (months 17-22), implementation support is discontinued.

+1 more arm

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Adoption - Electronic Health Records (EHR) Prior to randomization; then 4, 10, 16, and 22 months post initial randomization.

    Data on SOGI will be extracted from EHRs at participating PHOs by NMHealth. This data will be reviewed to calculate the percentage of patients with SOGI data collection recorded out of the total patients seen over the two months prior to the assessment. This is the outcome for which the SMART is powered.

Lead sponsor's other trials

Pacific Institute for Research and Evaluation, most recent start first.